Zymeworks Inc.NASDAQ: ZYME

Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting ADC ZW191 at ESMO Gynaecological Cancers Congress 2026

· Issued by Zymeworks Inc.
Watch Zymeworks explain itZymeworks Inc. (ZYME) Q1 2026 Earnings Call · Replay · May 7
  • ZW191 demonstrates compelling anti-tumor activity in platinum-resistant ovarian cancer patients regardless of FRα expression level
  • Confirmed objective response rate (cORR) of 78.6% in FRα-positive (≥75% at PS2+) platinum-resistant ovarian cancer patients and 47.4% in FRα-negative patients (

Earlier from Zymeworks

All Zymeworks news releases